Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
10.01. | IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree | ||
10.01. | 4DMT tosses 2 programs, halts funds for 3 others as it zeroes in on latest-stage clinical gene therapy | ||
10.01. | Kardigan launches with cozy $300M series A and collection of late-stage cardio assets | ||
10.01. | Saluda Medical toasts $100M fundraising to pep up sales of its closed-loop neurostimulator | ||
10.01. | AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia | ||
10.01. | Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund | ||
10.01. | Novo Holdings-backed Windward generates $200M series A, inks $970M biobucks deal for clinical antibody | ||
10.01. | Biotech creator and China's Keymed launch antibody company with $180M series A | ||
10.01. | Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect | ||
10.01. | Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial | ||
10.01. | Bausch + Lomb pens $485M-plus biobucks pact with City Tx for RNAi eye disease work | ||
10.01. | Repare cans plans for phase 3 cancer combo trial in latest money-saving move | ||
10.01. | Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline | ||
08.01. | Sana's cell therapy may be 'transformative cure' for type 1 diabetes: analysts | ||
08.01. | Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes | ||
08.01. | LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push | ||
08.01. | Galapagos splits in two, laying off 40% of staff, shrinking pipeline and ending Gilead partnership | ||
08.01. | Sanofi inks $400M biobucks deal to test the mettle of Alloy's antisense platform | ||
08.01. | Cassava lays off 3rd of workforce in wake of phase 3 Alzheimer's fail | ||
07.01. | Global CRO QPS makes Ryght choice for AI to automate clinical trials | ||
07.01. | FIRE1 heats up with $120M for its heart failure monitor implant | ||
07.01. | Stryker inks $4.9B deal for blood clot buster Inari Medical | ||
07.01. | AbbVie exercises first $40 million option to advance Capsida-partnered CNS gene therapy | ||
07.01. | Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data | ||
07.01. | Aviceda raises $207M series C to take geographic atrophy drug through phase 3 |